Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

ClinicalTrials.gov ID: NCT01120691

Public ClinicalTrials.gov record NCT01120691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Study identification

NCT ID
NCT01120691
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
2,224 participants

Conditions and interventions

Interventions

  • QVA149 Drug
  • NVA237 Drug
  • tiotropium Drug
  • Salbutamol/albuterol Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2010
Primary completion
Jun 30, 2012
Completion
Jun 30, 2012
Last update posted
Dec 1, 2013

2010 – 2012

United States locations

U.S. sites
53
U.S. states
25
U.S. cities
49
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35233
Novartis Investigative Site Fairhope Alabama 36532
Novartis Investigative Site Florence Alabama 35630
Novartis Investigative Site Homewood Alabama 35209-6870
Novartis Investigative Site Jasper Alabama 35501
Novartis Investigative Site Pine Bluff Arkansas 71603
Novartis Investigative Site Fullerton California 92835
Novartis Investigative Site Palo Alto California 94304-1207
Novartis Investigative Site Riverside California 92506
Novartis Investigative Site San Diego California 92101
Novartis Investigative Site San Diego California 92103-8415
Novartis Investigative Site San Diego California 92120
Novartis Investigative Site Stockton California 95207
Novartis Investigative Site Gainesville Florida 32608
Novartis Investigative Site Miami Florida 33125
Novartis Investigative Site Pensacola Florida 32503
Novartis Investigative Site Couer D'Alene Idaho 83814
Novartis Investigative Site Normal Illinois 61761
Novartis Investigative Site River Forest Illinois 60305
Novartis Investigative Site Florence Kentucky 41042
Novartis Investigative Site Louisville Kentucky 40206
Novartis Investigative Site Opelousas Louisiana 70570
Novartis Investigative Site Bangor Maine 04401
Novartis Investigative Site Fridley Minnesota 55432
Novartis Investigative Site Ozark Missouri 65721
Novartis Investigative Site Saint Charles Missouri 63301
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Missoula Montana 59804
Novartis Investigative Site Papillion Nebraska 68046
Novartis Investigative Site Henderson Nevada 89014
Novartis Investigative Site Las Vegas Nevada 89119
Novartis Investigative Site Reno Nevada 89520
Novartis Investigative Site Great Neck New York 11021
Novartis Investigative Site Massapequa New York 11758
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Raleigh North Carolina 27607
Novartis Investigative Site Wilmington North Carolina 28401
Novartis Investigative Site Columbus Ohio 43213
Novartis Investigative Site Medford Oregon 97504-8741
Novartis Investigative Site Portland Oregon 97213
Novartis Investigative Site Beaver Pennsylvania 15009
Novartis Investigative Site Erie Pennsylvania 16508
Novartis Investigative Site Pittsburgh Pennsylvania 15243
Novartis Investigative Site Charleston South Carolina 29406-7108
Novartis Investigative Site Spartanburg South Carolina 29303
Novartis Investigative Site Dallas Texas 75216
Novartis Investigative Site Dallas Texas 75246
Novartis Investigative Site Fort Worth Texas 76104
Novartis Investigative Site Fort Worth Texas 76107
Novartis Investigative Site Salt Lake City Utah 84107
Novartis Investigative Site Salem Virginia 24153
Novartis Investigative Site Tacoma Washington 98405
Novartis Investigative Site Green Bay Wisconsin 54311

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 289 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01120691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 1, 2013 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01120691 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →